GO
Loading...

Roche Holding AG

More

  • MADRID, Sept 30- A raft of new cancer drugs promise better, longer-lasting treatments with fewer adverse side effects-- but their high cost is a growing concern. Price-- just as much as safety and efficacy-- has proved a hot topic for nearly 20,000 oncology experts at the European Society for Medical Oncology annual congress in Madrid.

  • Ahead of the Bell: Exelixis shares soar Monday, 29 Sep 2014 | 9:19 AM ET

    SOUTH SAN FRANCISCO, Calif.— Shares of Exelixis jumped Monday before markets opened and after the drugmaker said its treatment for a deadly form of skin cancer fared better than another drug in a late-stage clinical study. Exelixis is partnering with Swiss drugmaker Roche Holding AG's Genentech to develop the drug.

  • *Roche set to compete with established GSK combination. *Shares in Roche's biotech partner Exelixis jump 20 pct. MADRID, Sept 29- Rival two-pill combinations for melanoma from Roche and GlaxoSmithKline had similarly good results in separate clinical trials, leaving doctors with little to choose between the two skin cancer courses.

  • *Perjeta builds on Roche's strong position in breast cancer. MADRID, Sept 28- A new breast cancer drug from Roche has shown "unprecedented" benefits in extending lives in a clinical trial and experts urged its widespread use for women with an aggressive form of the disease.

  • MADRID, Sept 28- Merck& Co's drug Keytruda, the first in a new wave of immune-boosting medicines to be approved for treating melanomas in the United States, also has potential in stomach cancer, new research shows.

  • *Perjeta builds on Roche's strong position in breast cancer. MADRID, Sept 28- A new breast cancer drug from Roche has shown "unprecedented" survival benefits in a clinical trial, boosting prospects for its widespread use in women with an aggressive form of the disease.

  • MADRID- ROCHE'S PERJETA DRUG ADDS 15.7 MONTHS SURVIVAL BENEFIT IN METASTATIC BREAST CANCER STUDY.

  • *AstraZeneca says tolerability profile encouraging. MADRID, Sept 27- Early results for a closely watched cancer drug combination from AstraZeneca that boosts the immune system show the cocktail is promising, though limited patient numbers mean the data is far from conclusive.

  • *AstraZeneca says tolerability profile encouraging. MADRID, Sept 27- Early results for a closely watched cancer drug combination from AstraZeneca that boosts the immune system suggest the cocktail is promising, though limited patient numbers mean the data is far from conclusive.

  • FDA warns doctors to beware fake drug distributors Tuesday, 23 Sep 2014 | 10:01 AM ET

    Beginning Tuesday the FDA will push back with its own educational campaign, faxing flyers to physicians across the country on how to recognize bogus offers and counterfeit drugs. One FDA flyer lists clues for spotting drugs that are not FDA- approved, including:. —a product name that differs from the name on an FDA- approved drug.

  • PARIS, Sept 18- French cancer immunotherapy specialist OSE Pharma has registered with market regulator AMF for an initial public offering aimed at financing late-stage trials of its Texopi drug for the most common form of lung cancer, the company said on Thursday.

  • For Roche CEO, celebrating failure is key to success Wednesday, 17 Sep 2014 | 8:06 AM ET

    LONDON, Sept 17- Roche Chief Executive Severin Schwan likes to crack open the champagne with his drug research teams at the end of a big project- especially when they fail.

  • LONDON, Sept 16- Roche's decision to buy U.S. biotech company InterMune for $8.3 billion last month was "exceptional" and not a sign of more ambitious plans for major acquisitions, the Swiss drugmaker's chief executive said on Tuesday.

  • Switzerland takes on its top drugmakers in price row Tuesday, 16 Sep 2014 | 5:46 AM ET

    *Roche, Novartis say low prices hurt R&D. ZURICH, Sept 16- Switzerland, home to the world's two biggest drugmakers, might be expected to give them an easy ride. But Roche and Novartis are finding no immunity in their home market from a European-wide price squeeze.

  • *Roche, Novartis say Lucentis is most appropriate drug. Avastin is not licensed for wAMD but it works in a similar way to authorized treatments for the condition- Lucentis, which is marketed by Novartis and Roche, and Eylea, from Bayer and Regeneron Pharmaceuticals.

  • Sept 12- Eli Lilly and Co's Cyramza stomach-cancer drug prolonged survival of patients with advanced colon cancer in a late-stage study, the U.S. drugmaker said on Friday. The 1,000- patient global study, called RAISE, involved patients who had previously failed to adequately benefit from Roche Holding AG's Avastin and other standard treatments.

  • *Departure a "loss" for Roche- analyst. ZURICH, Sept 4- Swiss drugmaker Roche said on Thursday that Art Levinson had resigned from its board of directors with immediate effect, in order to avoid any conflict of interest given his role as chief executive at Google's Calico.

  • Sept 3- U.S. drugmaker AbbVie Inc and Calico, a new company set up by Google Inc to cure diseases of aging, will each invest $250 million to help create Calico research facilities and collaborate on discovery and development of new medicines.

  • AbbVie, Calico forge deal against age-related diseases Wednesday, 3 Sep 2014 | 1:03 PM ET

    Sept 3- U.S. drugmaker AbbVie Inc and Calico, a new company set up by Google Inc to cure diseases of aging, will each invest $250 million to help create Calico research facilities and collaborate on discovery and development of new medicines.

  • Weaker healthcare stocks weigh on European equities Tuesday, 2 Sep 2014 | 12:40 PM ET

    *Bid target AstraZeneca falls; CEO says "back to normal". LONDON, Sept 2- A fall in major healthcare stocks, after drugmaker AstraZeneca tried to play down speculation about a new bid from Pfizer, pegged back European stock markets on Tuesday. "We wouldn't chase stocks at these levels," said HED Capital head Richard Edwards.